Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Expansion of Gastrointestinal Care: QIAGEN Introduces Molecular Test to QIAstat-Dx Syndromic Testing Menu in the U.S.

NextEdge Admin

03 Jun 2024

3 min 22 sec

QIAGEN, a leading global provider of Sample to Insight solutions, has launched the QIAstat-Dx Gastrointestinal Panel 2 in the United States, following its recent FDA clearance for clinical use. This syndromic test marks a significant advancement in gastrointestinal (GI) infection diagnosis by simultaneously detecting up to 16 clinically relevant bacterial, viral, and parasitic pathogens in about an hour.

Gastrointestinal infections, causing symptoms like acute infectious gastroenteritis, contribute to a substantial burden on healthcare systems, with an estimated 180 million cases annually in the U.S. Traditional microbiological testing methods often require prolonged incubation periods and specimen collection, whereas the QIAstat-Dx Gastrointestinal Panel 2 leverages real-time PCR technology to rapidly amplify multiple genetic targets in a single reaction. This approach not only enhances diagnostic accuracy but also expedites the time to results.

The panel’s software interprets reaction signals to provide positive or negative outcomes for each pathogen, along with cycle threshold values and amplification curves, offering additional insights compared to end-point PCR or other techniques. This comprehensive approach aids medical professionals in swiftly identifying the causative agent of GI illness, addressing challenges in distinguishing between viral, bacterial, and parasitic infections.

Furthermore, the QIAstat-Dx Gastrointestinal Panel 2 complements QIAGEN’s existing syndromic testing menu in the U.S., which includes the QIAstat-Dx Respiratory Panel Plus for respiratory infections. By facilitating prompt pathogen identification, these syndromic tests enable healthcare providers to isolate at-risk individuals, reduce unnecessary testing and treatment costs, and support antimicrobial stewardship efforts.

Syndromic testing has been shown to improve the detection of co-infections, potentially eliminating the need for additional diagnostic procedures such as endoscopies. Moreover, the ability to swiftly identify viral pathogens can help healthcare providers make informed decisions, leading to more targeted treatment strategies and reduced overall antibiotic usage.

QIAGEN’s syndromic testing solutions are available in over 100 countries, providing automated and reliable pathogen detection for hospitals, laboratories, and clinics worldwide. The QIAstat-Dx system, available in standard and higher-capacity versions, supports comprehensive testing and can be connected to the QIAsphere cloud-based platform for remote monitoring and epidemiological surveillance.